Vir Biotechnology, Inc. VIR
11.22 USD +0.22 (+2.00%)
At closeNov 3, 2026, 4:32 PM EST
11.22 0.00 0.00%
After hours · Nov 3, 4:32 PM ET
11.10 Day range 11.38
4.82 52-week range 12.19
- YTD
- +86.07%
- 1 year
- +100.36%
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 21.00 +87.2% upside
Now 11.22
- Target (low)
- 15.00
- Target (mean)
- 21.00
- Target (high)
- 30.00
Ratings (0m) 9 9 buy · 0 hold · 0 sell
- Strong buy3
- Buy6
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 9
- 1 month ago 10
- 2 months ago 10
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.74517 | -0.95 – -0.58 | -1.17 | +36.3% | 1.38M | +475.0% | 6 |
| Next quarter | -0.62283 | -0.78 – -0.487 | -0.31 | -100.9% | 6.20M | -90.3% | 6 |
| Current year | -1.77 | -2.22 – -1.37 | -3.16 | +44.0% | 239.48M | +249.3% | 6 |
| Next year | -2.47 | -2.94 – -1.57 | -1.77 | -39.3% | 76.27M | -68.2% | 6 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 7, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Jun 11, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
| Jun 3, 2026 | Leerink Partners | Maintained | Outperform | Outperform |
| Mar 4, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Feb 25, 2026 | Barclays | Maintained | Overweight | Overweight |
| Feb 24, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
| Feb 24, 2026 | Evercore ISI Group | Maintained | Outperform | Outperform |
| Feb 24, 2026 | Needham | Maintained | Buy | Buy |
| Feb 9, 2026 | Needham | Reiterated | Buy | Buy |
| Dec 30, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Sep 15, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Sep 3, 2025 | Evercore ISI Group | Initiated | — | Outperform |
| Aug 27, 2025 | B of A Securities | Upgrade | Neutral | Buy |
| Jul 11, 2025 | Raymond James | Initiated | — | Outperform |
| May 22, 2025 | Needham | Reiterated | Buy | Buy |
| May 12, 2025 | Needham | Maintained | Buy | Buy |
| Apr 17, 2025 | Goldman Sachs | Maintained | Buy | Buy |
| Feb 28, 2025 | Barclays | Maintained | Overweight | Overweight |
| Feb 28, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Feb 27, 2025 | Needham | Reiterated | Buy | Buy |
| Jan 31, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jan 13, 2025 | Leerink Partners | Maintained | Outperform | Outperform |
| Jan 10, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jan 9, 2025 | Morgan Stanley | Upgrade | Equal-Weight | Overweight |
| Jan 9, 2025 | JP Morgan | Maintained | Neutral | Neutral |
| Nov 20, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Nov 20, 2024 | Needham | Reiterated | Buy | Buy |
| Nov 4, 2024 | Barclays | Maintained | Overweight | Overweight |
| Nov 4, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Nov 1, 2024 | Needham | Reiterated | Buy | Buy |